<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>PURPOSE: A case of bilateral <z:hpo ids='HP_0001085'>papilledema</z:hpo> secondary to cerebral venous sinus <z:mp ids='MP_0005048'>thrombosis</z:mp> treated with Rituximab, an anti-CD20 monoclonal antibody </plain></SENT>
<SENT sid="1" pm="."><plain>METHODS: A 23 year old <z:mp ids='MP_0001261'>obese</z:mp> female with a one week history of <z:hpo ids='HP_0000622'>blurred vision</z:hpo>, <z:hpo ids='HP_0002315'>headaches</z:hpo> and <z:hpo ids='HP_0002013'>vomiting</z:hpo> presented with bilateral <z:hpo ids='HP_0001085'>papilledema</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>Her BCVA was 20/50 in right eye and 20/200 in the left eye with severe reduction of visual fields </plain></SENT>
<SENT sid="3" pm="."><plain>Laboratory investigations revealed <z:hpo ids='HP_0001873'>thrombocytopenia</z:hpo>, <z:hpo ids='HP_0008151'>prolonged prothrombin time</z:hpo> (not reversed when mixed with <z:mpath ids='MPATH_458'>normal</z:mpath> plasma) and anticardiolipin antibodies </plain></SENT>
<SENT sid="4" pm="."><plain>Besides, cerebral angiogram showed presence of <z:hpo ids='HP_0005305'>cerebral venous thrombosis</z:hpo> </plain></SENT>
<SENT sid="5" pm="."><plain>The patient to have anti <z:chebi fb="0" ids="16247">phospholipid</z:chebi> antibody syndrome and treated with rituximab I.V </plain></SENT>
<SENT sid="6" pm="."><plain>375 mg/m 2 weekly x 4 doses, <z:chebi fb="0" ids="27690">acetazolamide</z:chebi> 500 mg BID, <z:chebi fb="36" ids="29309">methyl</z:chebi> <z:chebi fb="2" ids="8378">prednisolone</z:chebi> I </plain></SENT>
<SENT sid="7" pm="."><plain>V </plain></SENT>
<SENT sid="8" pm="."><plain>QID x 4 </plain></SENT>
<SENT sid="9" pm="."><plain>RESULTS: At 1-month, her <z:hpo ids='HP_0002315'>headaches</z:hpo> and vision improved to 20/30 in both eyes with partial resolution of <z:hpo ids='HP_0001085'>papilledema</z:hpo> and complete restoration of visual fields </plain></SENT>
<SENT sid="10" pm="."><plain>Nine months later, patient had 20/25 vision in right eye and 20/30 in left eye with complete resolution of <z:hpo ids='HP_0001085'>papilledema</z:hpo> and cerebral sinus <z:mp ids='MP_0005048'>thrombosis</z:mp> </plain></SENT>
<SENT sid="11" pm="."><plain>CONCLUSIONS: Rituximab was effective in reversing <z:hpo ids='HP_0001085'>papilledema</z:hpo> and cerebral sinus <z:mp ids='MP_0005048'>thrombosis</z:mp>, while preserving the vision in patient with <z:hpo ids='HP_0003613'>antiphospholipid antibody</z:hpo> syndrome </plain></SENT>
<SENT sid="12" pm="."><plain>It is efficacious in treating <z:hpo ids='HP_0001085'>papilledema</z:hpo> in patients refractory to treatment with systemic steroids and immunoglobulin, with better clinical compliance and no side effects </plain></SENT>
</text></document>